Antibody–drug conjugates in lung cancer: current landscape and future perspectives

Current Opinion in Oncology · Published 2025-10-22 · DOI 10.1097/cco.0000000000001200

Authors being retrieved — see the publisher record. https://doi.org/10.1097/cco.0000000000001200

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives · MedComm · 2026 · Cites or is cited by this article
• State of the art and future directions in the treatment of metastatic adenoid cystic carcinoma · Current Opinion in Oncology · 2025 · Same journal
• High-risk smoldering myeloma – a case for early intervention? · Current Opinion in Oncology · 2025 · Same journal
• Artificial intelligence for systemic therapy selection and prediction of outcomes in advanced gynecological cancers · Current Opinion in Oncology · 2026 · Same journal
• Curative strategies for high-risk acute promyelocytic leukemia · Current Opinion in Oncology · 2025 · Same journal
• The evolving landscape of bispecific antibodies in the treatment of lung cancer · Current Opinion in Oncology · 2025 · Same journal
• Circulating tumor DNA in human papilloma virus negative head and neck squamous cell carcinoma · Current Opinion in Oncology · 2026 · Same journal
• Immunotherapy in rare histologies of breast cancer: challenges, opportunities, and future perspectives · Current Opinion in Oncology · 2025 · Same journal
• Emerging role of functional imaging in renal cell carcinoma: from morphology to molecular phenotyping with PET/computed tomography · Current Opinion in Oncology · 2026 · Same journal
• Desmoplastic small round cell tumor · Current Opinion in Oncology · 2026 · Same journal